Skip to main content
enGene Holdings Inc. logo

enGene Holdings Inc. — Investor Relations & Filings

Ticker · ENGN ISIN · CA29286M1059 LEI · 529900NE5JFN74BYXQ13 US Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2023-12-26 Regulatory Filings
Country CA Canada
Listing US ENGN

About enGene Holdings Inc.

https://engene.com/

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-12-26 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new director to the Board of Directors, including details about the director's term, committee assignment, and compensation plan. There is no financial data or detailed report content, but rather an announcement of a board/management change. This fits the category of Board/Management Information (MANG). The document length is 5221 characters, which is sufficient to contain substantive information about the board change, not just a brief announcement. Therefore, the classification is MANG with high confidence.
2023-12-20 English
Director's Dealing 2023
Director's Dealing
2023-12-19 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by enGene Holdings Inc. The letter addresses specific SEC comments and the company's responses, including revisions to the prospectus and disclosures related to the registration statement. The document references the Form S-1 registration statement and its amendment, which is a filing used for securities registration, not a financial report or earnings release. The content is a regulatory correspondence related to the registration process rather than a financial report, earnings release, or other types of filings. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence and does not contain financial statements or detailed financial data itself.
2023-12-15 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement Amendment No. 1 filed with the U.S. Securities and Exchange Commission. It is a preliminary prospectus related to the registration of securities for public offering, including common shares and warrants. The text includes detailed information about the securities being registered, selling holders, offering details, risk factors, use of proceeds, management discussion and analysis, executive compensation, and other related disclosures typical of a registration statement for an initial or secondary public offering. This is not an annual report, earnings release, or any other financial report but a regulatory filing for securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2023-12-15 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 13, 2023. It announces the appointment and employment agreement of a new Chief Financial Officer, Ryan Daws, including details of his compensation and severance terms. The content focuses on management changes and employment agreements rather than financial results, audit information, or other report types. The document is not a full financial report but a regulatory filing announcing a management change. Therefore, it fits best under Board/Management Information (MANG). The document length is 6403 characters, which is sufficient for a detailed announcement but not a full report like an Annual or Interim Report. Hence, the classification is MANG with high confidence.
2023-12-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.